FDA CBER
How the Center for Biologics Evaluation and Research regulates vaccines in
the United States.
The Center for Biologics Evaluation and Research (CBER) is the branch of
the U.S. Food and Drug Administration (FDA) responsible for ensuring the
safety, efficacy, and quality of biologics, including vaccines. CBER
regulates vaccines under the Federal Food, Drug, and Cosmetic Act and the
Public Health Service Act.
Organizational Structure
CBER is led by the Director and comprises several offices responsible for
different aspects of biologic regulation:
-
Office of Vaccines Research and Review: Reviews vaccine
clinical trials, manufacturing, and labeling
-
Office of Biostatistics and Epidemiology: Analyzes
clinical trial data and post-market safety data
-
Office of Compliance: Ensures manufacturers meet
regulatory standards
-
Office of Cellular, Tissue, and Gene Therapies:
Regulates advanced therapies
-
Office of Technology and Innovation: Supports
innovation in biologic development
The Vaccine Review Process
When a vaccine manufacturer seeks approval, CBER conducts a comprehensive
review:
-
Pre-IND meetings: Regulatory guidance before clinical
trials begin
-
IND (Investigational New Drug) review: Oversight of
clinical trial phases
-
BLA (Biologics License Application) review:
Comprehensive evaluation of all data
-
Facility inspections: Manufacturing plant verification
-
Labeling review: Package insert and patient information
-
Approval decision: License granted if benefits outweigh
risks
The Role of Advisory Committees
CBER often convenes advisory committees to provide independent expert
advice:
-
Vaccines and Related Biological Products Advisory Committee
(VRBPAC):
Primary committee for vaccine review
- Committee reviews data and votes on regulatory questions
- Recommendations are advisory; final decision rests with FDA
- Meetings are public and webcast for transparency
Enforcement Authority
CBER has broad authority to enforce regulatory standards:
-
License suspension or revocation: Can halt vaccine
distribution
-
Warning letters: Formal communication requiring
corrective action
-
Product recalls: Can require removal of unsafe products
-
Civil and criminal penalties: For regulatory violations
Sources & Citations